BofA analyst Michael Ryskin raised the firm’s price target on 10x Genomics (TXG) to $18 from $15 and keeps a Neutral rating on the shares. The firm is updating it price targets for Life Sciences & ...

During today's call, I'll start with a brief overview of the product launches and foundational progress we made in 2024 and ...

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 6.3% in the morning session after Citigroup ...

10x Genomics, Inc. (NASDAQ:TXG) is one of the best digital health stocks to buy now. On October 29, 2025, 10x Genomics announced the launch of its next-generation Chromium Flex assay, designed to help ...

10x Genomics is one of the pioneers in single-cell analysis and spatial biology, having developed equipment in this field since its foundation in 2012. One of its founders, Serge Saxonov, was ...

Located on the Buffalo Niagara Medical Campus and the first next-generation sequencing service provider in the region, UB's Genomics and Bioinformatics Core Facility provides high-quality services ...

10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as ...

New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of studies PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc.

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables ...